<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234935</url>
  </required_header>
  <id_info>
    <org_study_id>TRIO-TORI PA-01</org_study_id>
    <secondary_id>NCI-2010-02190</secondary_id>
    <nct_id>NCT01234935</nct_id>
  </id_info>
  <brief_title>Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery</brief_title>
  <official_title>A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Oncology Research International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Oncology Research International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. It is not yet known whether giving dasatinib together with&#xD;
      gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating&#xD;
      pancreatic cancer. PURPOSE: This randomized phase II trial is studying how well giving&#xD;
      dasatinib together with gemcitabine hydrochloride works compared to giving gemcitabine&#xD;
      hydrochloride alone in treating patients with pancreatic cancer previously treated with&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To compare disease-free survival at 18 months between&#xD;
      dasatinib-gemcitabine combination therapy and single-agent gemcitabine. SECONDARY OBJECTIVES:&#xD;
      I. To evaluate effects on disease-free survival of the dasatinib-gemcitabine combination&#xD;
      therapy compared with gemcitabine alone for adjuvant treatment of resected pancreatic&#xD;
      adenocarcinoma. II. To evaluate effects on overall survival of dasatinib-gemcitabine&#xD;
      combination therapy compared with gemcitabine alone for adjuvant treatment of resected&#xD;
      pancreatic adenocarcinoma. III. To evaluate tolerability and safety of the two arms. IV. To&#xD;
      identify potential biological correlates associated with clinical benefit to&#xD;
      dasatinib-gemcitabine combination therapy compared with gemcitabine alone. OUTLINE: Patients&#xD;
      are randomized to 1 of 2 treatment arms. ARM I: Patients receive gemcitabine hydrochloride IV&#xD;
      on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. ARM II: Patients receive gemcitabine hydrochloride IV&#xD;
      on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28&#xD;
      days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *&#xD;
      Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression&#xD;
      or unacceptable toxicity. After completion of study treatment, patients are followed up every&#xD;
      3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2011</start_date>
  <completion_date type="Actual">November 27, 2017</completion_date>
  <primary_completion_date type="Actual">November 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>At 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>follow-up every 3 months for 30 months from first treatment or until disease recurrence or withdrawal of consent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Acinar Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Duct Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage IA Pancreatic Cancer</condition>
  <condition>Stage IB Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>dFdCyd</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Gene Sequencing</other_name>
    <other_name>Molecular Biology, Nucleic Acid Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent before beginning any protocol specified procedures&#xD;
&#xD;
          -  Histologically proven pancreatic adenocarcinoma&#xD;
&#xD;
          -  Any T, any N, M0 disease that has had all gross disease resected (R0 or R1 resection)&#xD;
&#xD;
          -  ECOG Performance status index 0 or 1&#xD;
&#xD;
          -  Absolute Neutrophils &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;= 10 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 2.0 x UNL; subjects with Gilbert's syndrome, confirmed by&#xD;
             genotyping or invader UGTIA1 molecular assay before study entry must have total&#xD;
             bilirubin &lt; 3 x UNL&#xD;
&#xD;
          -  ASAT (SGOT) and ALAT (SGPT) =&lt; 2.5 x UNL&#xD;
&#xD;
          -  Alkaline Phosphatase =&lt; 5 x UNL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 x UNL&#xD;
&#xD;
          -  Serum Na, K+, Magnesium, Phosphate and Calcium &gt;= LNL&#xD;
&#xD;
          -  First study treatment must be given within 60 days after surgery and within 7 days&#xD;
             after randomization&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow-up and compliant with study&#xD;
             procedures&#xD;
&#xD;
          -  Negative pregnancy test (urine or serum) within 7 days before first study treatment&#xD;
             for all women of childbearing potential, whom also must implement adequate&#xD;
             non-hormonal contraceptive measures during study treatment and for at least 3 months&#xD;
             after the last dose of study therapy&#xD;
&#xD;
          -  Ability to take oral medication (dasatinib must be swallowed whole)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or concurrent systemic anticancer therapy (immunotherapy, hormonal therapy,&#xD;
             biological therapy, or chemotherapy) for pancreatic cancer&#xD;
&#xD;
          -  Prior or concurrent radiation therapy for pancreatic cancer&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  M1 pancreatic cancer&#xD;
&#xD;
          -  Concurrent congestive heart failure, unstable angina pectoris, or M1 within the 6&#xD;
             months before first study treatment&#xD;
&#xD;
          -  Uncontrolled hypertension or high-risk uncontrolled arrhythmias&#xD;
&#xD;
          -  Any history of clinically significant ventricular arrhythmias (such as ventricular&#xD;
             tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
          -  Diagnosed or suspected congenital long QT syndrome&#xD;
&#xD;
          -  Prolonged QTc interval on pre-entry electrocardiogram (&gt; 450 msec)&#xD;
&#xD;
          -  History of significant neurologic or psychiatric disorders including psychotic&#xD;
             disorders, dementia or seizures that would prohibit the understanding and giving of&#xD;
             informed consent&#xD;
&#xD;
          -  Past or current history of neoplasm other than pancreatic adenocarcinoma, except for:&#xD;
             curatively treated non-melanoma skin cancer; in situ carcinoma of the cervix; other&#xD;
             cancer curatively treated and with no evidences of disease for at least 1 year&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or treatment with investigational&#xD;
             drugs within 30 days of first study treatment&#xD;
&#xD;
          -  Currently receiving drugs with known significant CYP 3A4 inhibitory effects (such as&#xD;
             ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil,&#xD;
             ritonavir, indinavir)&#xD;
&#xD;
          -  Concurrent administration with inducers of CYP 3A4 may result in a lower exposure to&#xD;
             dasatinib and are therefore not allowed (e.g., phenytoin, carbamazepine, rifampicin,&#xD;
             phenobarbital, pentobarbital, or St John's Wort)&#xD;
&#xD;
          -  Known allergy reactions to dasatinib or gemcitabine or excipients used in the study&#xD;
&#xD;
          -  History of significant bleeding disorders unrelated to cancer, including: diagnosed&#xD;
             congenital bleeding disorders (e.g., Von Willebrand's disease); diagnosed acquired&#xD;
             bleeding disorder within 1 year (e.g., acquired anti-factor VIII antibodies); ongoing&#xD;
             or recent (=&lt; 3 months) significant gastrointestinal bleeding&#xD;
&#xD;
          -  Patients currently taking drugs that are generally accepted to have a risk of causing&#xD;
             Torsades De Pointes including: quinidine, procainamide, disopyramide; amiodarone,&#xD;
             sotalol, ibutilide, dofetilide; erythromycins, clarithromycin; chlorpromazine,&#xD;
             haloperidol, mesoridazine, thioridazine, pimozide; cisapride, bepridil, droperidol,&#xD;
             methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine,&#xD;
             sparfloxacin, lidoflazine&#xD;
&#xD;
          -  Concurrent treatment with intravenous bisphosphonates; prior treatment should be&#xD;
             stopped at least 2 weeks before first dose of study treatment&#xD;
&#xD;
          -  Concurrent medical condition which may increase the risk of toxicity, including&#xD;
             pleural or pericardial effusion or any grade&#xD;
&#xD;
          -  Active uncontrolled infection requiring parenteral antimicrobials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Finn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Oncology Research International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI FULLERTON (St. Jude Heritage Healthcare Virginia K. Crosson Cancer Center)</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA medical center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024-3417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Translational Oncology Research International (TORI) Network</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI NORTHRIDGE (North Valley Hematology/Oncology Medical Group)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI Inland Valley (Wilshire Oncology Medical Group, Inc. )</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.)</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI SANTA BARBARA I (Santa Barbara Hematology Oncology Medical Group, Inc.)</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI SANTA BARBARA II (SANSUM Clinic)</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TORI SANTA MARIA (Central Coast Medical Oncology Corporation)</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Valencia</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hematology-Oncology Associates, P.A.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Healthcare Management, LLC</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Acinar Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

